A new report suggests that biopharmaceutical companies are expressing strong interest in the Chinese marketplace. “Heading East: Biopharma International Expansion to China and Asia,” a report developed by us at BIO and L.E.K. implies that because of intellectual property rights and other regulations biopharma companies will only be willing to enter into the Chinese market if they first partner with a Chinese firm. Joint ventures are, according to the report, the only way we will see the full potential of the Chinese marketplace actualized.
For more information read this press release.